Quoin Pharmaceuticals (QNRX) Share-based Compensation (2022 - 2026)
Quoin Pharmaceuticals (QNRX) posted Share-based Compensation of $7.3 million for Q1 2026, up 2452.72% sequentially from $285969.0 in Q4 2025, and up 1925.77% YoY from $360357.0 in Q1 2025.
Quoin Pharmaceuticals (QNRX) Share-based Compensation (2022 - 2026) Analysis & Trends
Quoin Pharmaceuticals has reported Share-based Compensation for 5 years, with the latest figure at $7.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 1925.77% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 455.83% YoY) and the FY2025 annual result came in at $2.5 million, down 13.79% from the prior year.
- Share-based Compensation improved to $7.3 million in Q1 2026 per QNRX's latest filing, from $285969.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $7.3 million in Q1 2026 and troughed at $182000.0 in Q3 2025.
- A 5-year average of $1.1 million and a median of $303256.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation slumped 92.94% in 2023, then jumped 1925.77% in 2026.
- Over 5 years, Share-based Compensation stood at $267007.0 in 2022, then increased by 12.43% to $300198.0 in 2023, then grew by 8.93% to $327000.0 in 2024, then declined by 12.55% to $285969.0 in 2025, then soared by 2452.72% to $7.3 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $7.3 million, $285969.0, and $182000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Quoin Pharmaceuticals | 491,038.58 | 491,038.58 | - | 6.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.30 Mn |
| Mar 31, 2026 | 7.30 Mn |
| Dec 31, 2025 | 285,969.00 |
| Dec 31, 2025 | 285,969.00 |
| Sep 30, 2025 | 182,000.00 |
| Sep 30, 2025 | 182,000.00 |
| Jun 30, 2025 | 3.10 Mn |
| Jun 30, 2025 | 3.10 Mn |
| Mar 31, 2025 | 360,357.00 |
| Mar 31, 2025 | 360,357.00 |
| Dec 31, 2024 | 327,000.00 |
| Dec 31, 2024 | 327,000.00 |
| Sep 30, 2024 | 313,000.00 |
| Sep 30, 2024 | 313,000.00 |
| Jun 30, 2024 | 313,000.00 |
| Jun 30, 2024 | 313,000.00 |
| Mar 31, 2024 | 306,314.00 |
| Mar 31, 2024 | 306,314.00 |
| Dec 31, 2023 | 300,198.00 |
| Dec 31, 2023 | 300,198.00 |